Chad Diamond, DO
Family Medicine · Hattiesburg, MSNPI 1124023098
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 431 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,468 and has fallen 50.8% since, to $722 in 2025. Among family medicine clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 431 payments — averaging $15.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- AstraZeneca$693
- Amgen$521
- Novo Nordisk$428
- Johnson & Johnson$323
- plus $2K from 32 others
What the payments were for
- Food & beverage$6,507100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 123 | $1,321 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 63 | $1,153 |
| AstraZeneca | 36 | $693 |
| Amgen | 39 | $521 |
| Novo Nordisk | 27 | $428 |
| Johnson & Johnson | 21 | $323 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $220 |
| GSK | 12 | $184 |
| Teva Pharmaceuticals USA, Inc. | 10 | $151 |
| Genentech USA, Inc. | 9 | $126 |
| Biohaven Pharmaceuticals, Inc. | 7 | $113 |
| Astellas Pharma US Inc | 7 | $109 |
| Amarin Pharma, Inc. | 6 | $106 |
| Pfizer | 7 | $101 |
| Boehringer Ingelheim | 6 | $101 |
| Sanofi-aventis U.S. LLC | 1 | $81 |
| Merck | 5 | $76 |
| Lilly USA, LLC | 4 | $70 |
| Shield Therapeutics Inc | 4 | $68 |
| Tris Pharma Inc | 4 | $61 |
| Idorsia Pharmaceuticals US Inc | 3 | $50 |
| Abbott | 2 | $46 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $46 |
| Novartis | 2 | $46 |
| Sunovion Pharmaceuticals Inc. | 2 | $40 |
| Exact Sciences | 2 | $37 |
| Medtronic | 2 | $34 |
| Bayer | 2 | $32 |
| Eisai Inc. | 2 | $28 |
| Shire North American Group Inc | 2 | $26 |
| IBSA Pharma Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Axonics, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
| Avanir Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$6,521 in reported general payments places this provider in the 90th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 60 | $91,475 |
| TrulicityDulaglutide | 54 | $54,774 |
| JardianceEmpagliflozin | 36 | $54,424 |
| JanuviaSitagliptin Phosphate | 45 | $34,607 |
| FarxigaDapagliflozin Propanediol | 50 | $33,299 |
| OzempicSemaglutide | 21 | $28,470 |
| EliquisApixaban | 38 | $28,141 |
| LinzessLinaclotide | 23 | $12,071 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $10,787 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $7,696 |
| Risedronate Sodium | 39 | $6,667 |
| SynthroidLevothyroxine Sodium | 55 | $4,590 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $4,523 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $3,825 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $3,637 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $70 | $146,249114 claims |
| Boehringer IngelheimJardiance | $101 | $54,42436 claims |
| AstraZenecaFarxiga, Symbicort | $693 | $44,08683 claims |
| MerckJanuvia | $76 | $34,60745 claims |
| Novo NordiskOzempic | $428 | $28,47021 claims |
| PfizerEliquis | $101 | $28,14138 claims |
| AbbVieLinzess, Synthroid | $1,321 | $16,66178 claims |
| GSKAnoro Ellipta | $184 | $4,52311 claims |
| Sanofi-aventis U.S. LLCLantus | $81 | $2,51312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Hattiesburg
- Omolara OtaigbeHattiesburg$17K
- Deborah CopelandHattiesburg$13K
- J DumasHattiesburg$12K
- Anny EvansHattiesburg$10K
- Melanie HallHattiesburg$10K
- Stephen LambertHattiesburg$9K
- Russell CarlisleWesson$1.6M
- Keith StokesLexington$654K
- Walter CarnahanSouthaven$146K
- Karen WhitneyWhitfield$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.